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Summary
AMPA-type glutamate receptors are specifically in-
hibited by the noncompetitive antagonists GYKI-
53655 and CP-465,022, which act through sites and
mechanisms that are not understood. Using receptor
mutagenesis, we found that these antagonists bind at
the interface between the S1 and S2 glutamate binding
core and channel transmembrane domains, specifi-
cally interactingwith S1-M1 andS2-M4 linkers, thereby
disrupting the transduction of agonist binding into
channel opening. We also found that the antagonists’
affinity is higher for agonist-unbound receptors than
for activated nondesensitized receptors, further de-
pending on the level of S1 and S2 domain closure.
These results provide evidence for substantial confor-
mational changes in the S1-M1 and S2-M4 linkers fol-
lowing agonist binding and channel opening, offering
a conceptual frame to account for noncompetitive an-
tagonism of AMPA receptors.
Introduction
AMPA receptors (AMPARs) are glutamate-gated ion
channels that mediate the majority of fast excitatory
synaptic transmissions in the mammalian brain. They
are part of a larger family of ionotropic glutamate recep-
tors (iGluRs) that includes the closely related kainate re-
ceptors (KAR) and the NMDA receptors (NMDARs) (Din-
gledine et al., 1999). Due to the critical role that these
receptors play at the synapse, there is great scientific
interest in elucidating the molecular basis of receptor
function. Dysregulation of glutamatergic synaptic trans-
mission is also implicated in a variety of neurodegener-
ative and neuropsychiatric conditions (Choi, 1992; Fran-
ciosi, 2001). Thus, achieving an understanding of the
way in which these receptors function may facilitate
the development of new therapies to treat diseases of
the central nervous system.
AMPARs assemble as tetramers in various combina-
tions of four homologous subunits, termed GluR1-4 (or
*Correspondence: yaelb@cc.huji.ac.ilGluR-A to -D) (Dingledine et al., 1999). Like all iGluR sub-
units, the AMPAR subunits share a modular design con-
sisting of an extracellular N-terminal oligomerization do-
main (NTD); an extracellular agonist-binding domain
formed by two segments, S1 and S2; a channel-forming
domain consisting of three transmembrane domains,
M1, M3, and M4 and a reentrant loop M2; and an intra-
cellular C-terminal trafficking and anchoring domain
(CTD) (Figure 3; Madden, 2002; McFeeters and Oswald,
2004). Currently, structural data at atomic resolution are
available only for the S1 and S2 domains, of which the
first and most extensively characterized is that derived
from the AMPAR GluR2 (Armstrong et al., 1998; Erreger
et al., 2004; Mayer and Armstrong, 2004). Collectively, it
has been shown that S1 and S2, which in the intact re-
ceptors are separated by the membrane regions M1 to
M3, fold in a special manner, creating two globular do-
mains (D1 and D2; Figure 4A, cartoon). Glutamate first
docks in D1, which then promotes the rotation of D2
and closure of the binding cleft. Full agonists like gluta-
mate and AMPA induce a large movement (w20º) result-
ing in full activation. Partial agonists like kainate induce
an intermediate closure (w12º) and partial activation,
and competitive antagonists like DNQX promote only
a small extent of domain closure that is insufficient to
trigger ion channel gating. Several studies have pro-
vided evidence that the agonist binding domains as-
semble as dimers, and the mechanism of desensitiza-
tion has been further defined as a rearrangement of
the dimer interface (Mayer and Armstrong, 2004; Sun
et al., 2002). Therefore, the idea that agonist binding
to S1 and S2 evokes significant conformational changes
in the extracellular domains leading to channel opening
is widely accepted. However, the mechanism by which
these conformational changes are transduced to chan-
nel gating is still unclear. Gating is likely to involve the
linker regions between the agonist-binding and channel-
forming domains, namely the S1-M1, S2-M3, and S2-M4
linkers (Figure 4A; cartoon). These regions are postu-
lated to contribute to an extended mass at the bottom
of D2 (Abele et al., 1999) and are therefore likely to be
coupled to the movement of D2 upon agonist binding.
So far, experimental evidence for such conformational
rearrangements is limited to the M3 linker (Erreger
et al., 2004; Wollmuth and Sobolevsky, 2004).
There are a number of pharmacological agents that
affect AMPAR function through interactions outside of
the agonist-binding domain (Kew and Kemp, 2005).
Thus, investigating the means by which binding of these
ligands modulate channel gating may provide additional
insight into mechanisms of receptor function. Toward
this end, we have investigated the site of interaction
with AMPAR of two selective noncompetitive AMPAR
antagonists, GYKI-53655 (GYKI) and CP-465,022 (CP).
GYKI belongs to a family of 2,3-benzodiazepines (Solyom
and Tarnawa, 2002), and it is a more potent and selec-
tive analog of GYKI-52466, the first identified AMPAR
noncompetitive antagonist (Donevan and Rogawski,
1993; Tarnawa et al., 1992). CP is a derivative of pira-
quilone and is w100-fold more potent than GYKI on
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et al., 2000). Radioligand-binding assays suggested
that the binding sites of these two compounds overlap
with one another but that this site is distinct from the ag-
onist-binding site (Lazzaro et al., 2002; Menniti et al.,
2000). These antagonists are not open-channel block-
ers nor do they affect channel desensitization (Donevan
and Rogawski, 1998; Lazzaro et al., 2002; Rammes
et al., 1998), suggesting a mechanism of action not in-
volving binding to the channel pore. However, there is
an allosteric interaction between GYKI and the inhibitor
of desensitization cyclothiazide (CTZ) (Donevan and Ro-
gawski, 1998; Rammes et al., 1998), suggesting that the
binding site for GYKI is affected by gating, although the
molecular mechanism for this interaction is not known.
Here we show that GYKI and CP bind with different
affinity to different gating states of the AMPAR. The
highest affinity is for the closed state, most likely the
resting rather than the desensitized state, and the low-
est is for the open state, further depending on agonist
efficacy to open the channel. Using AMPA/kainate chi-
meras, we show that GYKI and CP bind at the linker re-
gions between S1 and S2 and the channel, specifically
interacting with S1-M1 and S2-M4. Therefore, the change
in antagonist binding affinity upon gating is indicative of
substantial conformational changes in these linkers fol-
lowing agonist binding and channel opening. A model in
which these noncompetitive inhibitors constrain the
movements of these linkers provides the insight into
the way agonist binding is transduced to channel gating
through the linker regions. As such, our study provides
a potential template for rational drug design.
Results
GYKI and CP are selective for inhibition of AMPAR com-
pared to KAR (Lazzaro et al., 2002; Paternain et al.,
1995). Consistent with these previous findings, GYKI
and CP completely inhibited glutamate-induced cur-
rents of the AMPAR subunit GluR3 expressed in Xeno-
pus oocytes at concentrations that had almost no effect
at the GluR6 KAR (Figures 1A and 1B). As previously
reported (Donevan and Rogawski, 1998; Palmer and
Lodge, 1993), the GYKI inhibitory potency (measured
as its IC50) was markedly decreased in the presence of
the desensitization blocker CTZ (w10-fold; Figure 1A).
This shift was initially interpreted as an evidence of
competition between GYKI and CTZ. However, later
studies suggested that this interaction is rather alloste-
ric. This was based on data from fast kinetic measure-
ments, showing no change in the desensitization onset
and recovery kinetics in the presence of GYKI and its in-
ability to reverse the action of CTZ (Donevan and Ro-
gawski, 1993, 1998; Rammes et al., 1998), the observa-
tion of a rather small shift in GYKI IC50 in the presence of
kainate, and the fact that mutations that largely affected
CTZ binding did not alter the sensitivity to GYKI (Partin
and Mayer, 1996). Figure 1B shows that CTZ also re-
duces the potency of CP to inhibit glutamate-induced
currents at a similar extent as seen for its effect on
GYKI. In addition, a previous study using radioligand-
binding assays found that CTZ does not interact directly
with the CP binding site (Menniti et al., 2000).GYKI and CP Bind with Different Affinity
to Different Gating States of the AMPAR
The above-described data further support an allosteric
interaction between the CTZ and GYKI/CP binding sites
and raise the hypothesis that the blocking of receptor
desensitization, rather than CTZ binding itself, is re-
sponsible for the effect on GYKI/CP potency. To test
this hypothesis, we measured GYKI and CP IC50s at
the nondesensitizing L-to-Y mutant of GluR3 (L507Y;
Stern-Bach et al., 1998) in the absence and presence
of CTZ. As seen in Figures 1A and 1B, the L-to-Y muta-
tion occluded the effect of CTZ on the ability of both
GYKI and CP to inhibit GluR3 receptors activated by
glutamate. Similar observations were made for L-to-Y
mutants of GluR1 and GluR2 receptors (Figure 1C). To
further examine the effect of receptor desensitization
on antagonist potency, we measured the ability of CP
to inhibit the activity of the partially desensitizing ago-
nist kainate in the absence or presence of CTZ. We
found that CP inhibits kainate-induced currents with
IC50 values slightly but significantly higher (w1.5-fold;
p < 0.05) than those obtained for currents induced by
the fully desensitizing agonists glutamate or AMPA
Figure 1. Effects of Receptor Desensitization and Agonist Efficacy
on GYKI/CP
(A and B) Representative dose-inhibition measurements of GYKI
(A) and CP (B) in the presence of 1 mM glutamate for GluR3 2 CTZ
(open circles), GluR3 + CTZ (solid circles), R3(L507Y) 2 CTZ (open
squares), R3(L507Y) + CTZ (solid squares), and GluR6 + ConA (solid
triangles). Responses (I) were normalized to glutamate-evoked cur-
rents without antagonist (I0). Each point is a mean (6SD) of five to ten
oocytes. GYKI IC50 values (mM): 7.6 6 0.5 (2CTZ), 73 6 3 (+CTZ) for
GluR3, and 946 4 (2CTZ), 946 7 (+CTZ) for R3(L507Y). CP IC50 val-
ues (mM): 0.36 0.1 (2CTZ), 3.06 0.3 (+CTZ) for GluR3, and 3.26 0.7
(2CTZ), 2.8 6 0.3 (+CTZ) for R3(L507Y).
(C) CP IC50 values (6SD) in the presence of kainate (1 mM), AMPA
(0.1 mM), or glutamate (1 mM) of wild-type (wt), GluR1, or GluR2 (un-
edited), without CTZ (white bars) or with CTZ (gray bars), and of
R1(L497Y) and R2(L504Y) without CTZ (black bars), measured as in
(B).
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281Figure 2. GYKI and CP Bind with Different
Affinity to Different Gating Modes
(A and B) Measurements of GYKI unbinding
rates from GluR1 receptors expressed in
HEK293 cells. (A) To measure the unbinding
rate of GYKI from the closed, nonactivated re-
ceptor channel, GYKI (30 mM) was applied to
the cell for 10–20 s and then washed out. After
several washout intervals (Dt), glutamate
(1 mM) was applied, and the instantaneous
evoked current was measured (arrowheads).
Data points (14 cells) were normalized to the
response in the absence of GYKI, pooled, and
fitted to a single exponential with the indi-
cated time constant (plot on the right). (B) To
measure the unbinding rate of GYKI from acti-
vated receptor channels, GYKI was applied
for 3.5 s once the receptors were activated
and then washed off. The time course of cur-
rent recovery denoted the unbinding rate of
GYKI (panel on the right), which was well fitted
by a single exponential of the indicated time
constant. Traces on the right correspond to the
recording fragment indicated by a box in (B).
(C–E) [3H]CP-specific binding to rat-brain membrane. (C) Binding of [3H]CP (3 nM) was measurend in the absence (control) or presence of gluta-
mate (Glu; 10 mM), AMPA (0.1 mM), kainate (3 mM), or CNQX (0.1 mM), with (black bars) or without (gray bars) CTZ. Values were normalized to
control without CTZ. Each bar is a mean (6SD) of three to four independent experiments done in triplicate (*p < 0.05, **p < 0.01). (D) [3H]CP-specific
binding (3 nM) to rat-brain membranes incubated with increasing glutamate concentrations, with (black circles) or without (gray circles) CTZ. Val-
ues were normalized to control (2CTZ/2glutamate). (E) Representative Scatchard plot analysis in the absence (control) or presence of AMPA (0.1
mM) and CTZ. Plots obtained in the presence of CTZ or AMPA alone were similar to control (data not shown). Mean Kd (6SEM) values were (nM):
3.7 6 0.5, n = 9 (control), 3.3 6 0.3, n = 3 (CTZ), 3.2 6 0.5, n = 3 (AMPA), and 24 6 7, n = 3 (AMPA + CTZ).(Figure 1C; compare white bars). The IC50 of CP for inhi-
bition of kainate-induced currents was increased a fur-
ther 2-fold in the presence of CTZ and in the L-to-Y mu-
tant receptor (Figure 1C). These 2-fold increases in IC50s
contrast with the 10-fold increases in the presence of
CTZ or the L-to-Y mutation when glutamate or AMPA
are the receptor activators (Figure 1C). Comparable re-
sults were observed for GYKI. Taken together, these re-
sults imply that gating state strongly affects the interac-
tion of GYKI and CP with the AMPAR. Furthermore, we
directly measured the unbinding rate of GYKI from both
unliganded and activated wild-type AMPARs, with the
idea that a change in receptor affinity for GYKI upon gat-
ing would be accurately indicated by its dissociation
rate constant. For these experiments, we expressed
the GluR1 subunit in HEK293 cells, and the GYKI disso-
ciation rate from unbound resting receptors was esti-
mated with the following protocol. Cells under recording
conditions were equilibrated with GYKI (30 mM) for 10–
20 s and then washed out for defined times before ap-
plying a pulse of glutamate (1 mM) (Figure 2A). Instanta-
neous responses increased with washout intervals
following a single exponential time course with a time
constant of 1.04 s (single exponential adjusted to pooled
data from 14 cells), which revealed the GYKI unbinding
rate from resting receptors. To measure the dissociation
rate from active GluR1 receptors, we applied a 3.5 s
pulse of GYKI in the continuous presence of glutamate
(Figure 2B). The current returned to the control value
upon GYKI removal. Such a relaxation was better ad-
justed by a biexponential process, being the slowest
one (t[ 1 s) of minor amplitude. Therefore, we used
the initial 1.5 s of the current relaxation to fit a single ex-
ponential, which on average presented a t of 563 6 179
ms (18 trials from 3 cells). These results indicate thatactive AMPARs present lower affinity for GYKI than rest-
ing nonactivated channels. We also evaluated direct
binding of noncompetitive antagonists in radioligand-
binding experiments using [3H]CP-526,427 ([3H]CP), a
radioactive analog of CP. For these investigations we
used purified rat-brain membranes (Menniti et al., 2000),
as [3H]CP-specific binding to recombinant receptors
expressed either in oocytes or in HEK293 cells was
too low for a reliable quantification (see Experimental
Procedures). To enrich for receptors in the different gat-
ing states, washed membranes were incubated with (1)
CTZ alone, enriching for the closed resting state; (2) ag-
onist alone, enriching for the closed desensitized state;
and (3) agonist + CTZ, enriching for the open state.
While no significant change was obtained with CTZ
alone or glutamate alone, in the presence of both CTZ
and glutamate we observed a significant reduction in
[3H]CP binding (Figure 2C) that depended on the con-
centration of glutamate (Figure 2D). In the presence of
CTZ, a similar decrease in [3H]CP binding was observed
for the other full-agonist AMPA (Figure 2C). However,
a smaller change was obtained for the partial-agonist
kainate, and no change was observed for the competi-
tive antagonist CNQX (Figure 2C). Scatchard plot analy-
sis demonstrated that the change in [3H]CP binding was
due to decreased binding affinity and not due to a de-
crease in the number of binding sites (Figure 2E). The
reduction in binding affinity could however be underes-
timated in these experiments, since CTZ is less effective
on AMPAR flop isoforms that are prevalently expressed
in the brain (Dingledine et al., 1999).
Based on these results we conclude that GYKI and
CP bind to the AMPAR with highest affinity to the closed
(resting and desensitized) state and with lowest affinity
to the open, nondesensitized state. Since GYKI has no
Neuron
282Figure 3. Subunit Sensitivity to GYKI and CP
Is Specified by Two Regions Conferring Op-
posite Sensitivity to Each Antagonist
(A) Description of GluR3/GluR6 chimeras
(GluR3, black bars; GluR6, white bars). Sub-
unit topographical domains are indicated
above the GluR6 bar (NTD, N-terminal w400
amino-acid domain; S1 and S2, agonist bind-
ing domain; vertical bars, transmembrane re-
gions M1, M3, and M4 and reentrant loop M2).
Asterisks indicate nondesensitizing chimeras
(Stern-Bach et al., 1998). The numbers in the
names of the chimeras indicate the amino
acids on the backbone subunit swapped
between GluR3 and GluR6 [for example,
R3(T810-I888) denotes that residues T810–
I888 in GluR3 were replaced by the corre-
sponding residues of GluR6].
(B) Inhibition of glutamate (1 mM) evoked
currents by GYKI (100 mM; black bars) or CP
(10 mM; gray bars). Currents were measured
in the presence of CTZ and/or ConA, as ap-
propriate, and inhibition values were normal-
ized to those obtained for GluR6 (GYKI,
5% 6 2%; CP, 4% 6 2%) and GluR3 (GYKI,
59% 6 8%; CP, 92% 6 7%) as follows: 1 2 (I/I0(mutant) 2 I/I0(R3))/(I/I0(R6) 2 I/I0(R3)). Each bar is a mean (6SD) of 20 to 40 oocytes collected from
at least two independent experiments. Note that GYKI concentrations higher than 100 mM could not be used due to the limited compound
solubility.effect on the onset of receptor desensitization (Figure
4C) or on its recovery from desensitization (Donevan
and Rogawski, 1998), GYKI/CP most likely stabilize
the resting state, thereby reducing the probability of
channel opening. Furthermore, because the antagonist
binding affinity inversely correlates with agonist effi-
cacy, we also suggest that agonist binding to S1 and
S2 and the subsequent ‘‘domain closure’’ leads to sub-
stantial conformational changes in the GYKI/CP binding
site, thereby altering the binding affinity. This suggested
that GYKI/CP bind to a site that is within the region of
the AMPAR that transduces agonist binding to channel
gating. To explore this possibility, we used a mutagene-
sis approach to identify the GYKI/CP binding site.
Receptor Sensitivity to GYKI and CP Is Conferred
by Residues in the S1-M1 and S2-M4 Linker Regions
To identify the GYKI/CP interacting site(s), we took ad-
vantage of the iGluR subtype selectivity of these com-
pounds and measured the ability of each antagonist to
inhibit the activity of various GluR3/GluR6 chimeras ex-
pressed in Xenopus oocytes. Because several of these
chimeras differ highly in their desensitization kinetics
and agonist efficacy profiles (Stern-Bach et al., 1994,
1998)—parameters found to also affect the GYKI/CP
inhibition potency—all measurements were done on
glutamate-induced currents in the presence of desensi-
tization blockers (CTZ and/or ConA as appropriate; see
Experimental Procedures). Collectively, the analysis of
the set of chimeras shown in Figure 3 narrowed down
the effects of GYKI and CP to two short segments,
one consisting of 30 residues preceding M1 [region I,
exemplified by chimera R3(F519-E548)], and the other
consisting of M4 and 7 preceding residues [region II, ex-
emplified by chimera R6(A812-G840)]. Exchanges con-
taining region I affected mainly the inhibitory potency
of CP [compare R6TM1R3 and R3(R6S1) to wild-type
GluR3], while exchanges containing region II weremore effective on GYKI [compare R3(T810-I888) to
wild-type GluR3, and R6(N654-G840) and R6(A812-
G840) to wild-type GluR6]. However, full conversion of
sensitivity was conferred only through the combination
of both regions I and II, as inferred from chimera R3(S1,
T810-I888).
Subsequent site-directed mutagenesis inside regions
I and II identified specific residues in each region repro-
ducing the effects seen for the larger exchanges (Tables
S1 and S2, respectively; see the Supplemental Data
available online). As summarized in Figure 4A, the resi-
dues affecting sensitivity to GYKI (marked by $) are
(for the most part) different from those affecting sensi-
tivity to CP (marked by D); however, they are in close
proximity to one another. In the intact receptor, these
residues are part of the peptides linking the C termini
of S1 and S2 to the respective trasmembrane domains
M1 and M4 and are here referred to as S1-M1 and S2-
M4 linkers (Figure 4A). Unfortunately, these linker se-
quences (as well as the S2-M3 linker) are omitted from
the crystallized S1 and S2 construct (Armstrong et al.,
1998).
Figure 4B further summarizes the impact of the spe-
cific amino-acid substitutions on the GYKI/CP sensitiv-
ity of GluR3 and GluR6, respectively, and reinforces at
the level of point mutations that while GluR3/GluR6 sub-
stitutions in S1-M1 were more potent on sensitivity to
CP and those in S2-M4 mainly affected sensitivity to
GYKI, full conversion of receptor sensitivity to either an-
tagonist depended on the reciprocal exchanges in both
S1-M1 and S2-M4 linkers. We further noted that while
the analysis shown in Figure 4B is in the presence of
desensitization blockers, when GluR3 mutants were
tested without CTZ, the antagonists’ potency increased
5- to 8-fold, as observed for wild-type GluR3 (Table S3).
Therefore, gating likely causes the same conformational
changes in each of the mutated linkers as in the wild-
type subunits leading to changes in antagonist efficacy.
Mechanism of AMPA Receptor Allosteric Inhibition
283Figure 4. Conversion of GYKI/CP Sensitivity
between GluR3 and GluR6 by Single Amino-
Acid Substitutions
(A) (Left) Schematic model of the organiza-
tion of S1 (black line) and S2 (gray line) form-
ing domains 1 and 2 (dark and light gray, re-
spectively) of the agonist-binding core. The
three linkers connecting S1 and S2 to the
transmembrane domains M1, M3, and M4
are marked as S1-M1, S2-M3, and S2-M4,
respectively. GluR3/GluR6 sequence align-
ment within parts of regions I and II (Figure
3) are shown on the right; amino-acid num-
bering is shown as superscript. The bound-
aries marked by S1* and S2* are according
to the crystallized S1 and S2 construct of
GluR2 (Armstrong et al., 1998), thus omitting
several amino acids N-terminal to M1 and
M4, marked as S1-M1 and S2-M4 linkers, re-
spectively. The signs $ and D indicate resi-
dues affecting sensitivity to GYKI and CP, re-
spectively.
(B) Inhibition of glutamate (1 mM) evoked
currents from oocytes expressing specific
mutations in S1-M1 and S2-M4 as indicated.
The mutant name denotes the amino acid
substituted between GluR3 and GluR6. An
exchange of more than one residue within
a specific region is indicated by the respec-
tive amino-acid numbering on the backbone
subunit [for example, R3(D543-E548) de-
notes the substitutions D543N, A546S,
Y547P, and E548D made on GluR3]. The ex-
periments were done in the presence of de-
sensitization blockers, as indicated, and the
mutants’ inhibition values were normalized
as described in Figure 3. Each bar is a mean
(6SD) of 20 to 40 oocytes collected from at
least two independent experiments.
(C) Inhibition of glutamate (3 mM) evoked cur-
rents from HEK293 cells expressing GluR1
(circles), GluR6 (squares), R6(G816S,G821A)
(up triangles), R6(N557D) (inverted triangles),
and R6(N557D,I820V) (stars). Three concen-
tration of CP (0.03, 0.3, and 3 mM) and one of
GYKI (30 mM) were tested. Cells were first exposed for 500 ms to 3 mM glutamate (I0), washed for 10 s, and than exposed for 1 s to the antagonist
alone, followed by a 500 ms application in the presence of glutamate (I). Each point is a mean (6SD) of three to five cells. Shown on the right are
representative superimposed normalized traces of GluR6, R6(G816S,G821A), and R6(N557D,I820V) without antagonist (control; light gray), plus
0.3 mM CP (gray), or 30 mM GYKI (black).Corresponding mutations in the AMPAR GluR1 subunit
produced similar effects on GYKI and CP sensitivity
(data not shown). For all subunit backgrounds, the mu-
tations affecting GYKI/CP sensitivity had no significant
effect on functional expression or glutamate EC50 as
compared to the wild-type subunits (data not shown).
Finally, measurements in HEK293 cells of peak current
responses of the GluR6 mutants, without blocking re-
ceptor desensitization, confirmed the results observed
in oocytes and also confirmed the observation made
on AMPAR that GYKI and CP do not alter onset of
receptor desensitization (Figure 4C; see Donevan and
Rogawski, 1998).
The simplest interpretation of the above results is that
GYKI and CP physically bind to the S1-M1/S2-M4 link-
ers, either to the particular identified residues or in their
vicinity. Interestingly, however, driven by the finding
that in NMDAR negative allosteric modulators such as
infenprodil and zinc bind to the NTD (Herin and Aizen-
man, 2004), a computer-modeling study suggestedhow GYKI may bind to the NTD of GluR1 (De Luca
et al., 2003). Therefore, it is possible that GYKI/CP inhi-
bition may result from allosteric interactions between
the NTD and the S1-M1/S2-M4 linkers. However, we
found that a GluR1 mutant lacking the NTD, which
was fully active (e.g., Pasternack et al., 2002), retained
the inhibition by GYKI and CP with IC50 values identical
for inhibition of the full-length receptor (data not shown),
therefore excluding the involvement of the NTD in GYKI/
CP binding.
In summary, the results show that residues responsi-
ble for sensitivity to GYKI and CP, although not identi-
cal, reside in two small regions of the AMPAR that link
the agonist-binding domain to the membrane-spanning
domains that form the AMPAR channel pore. This sug-
gests that the GYKI/CP binding site is located in regions
hypothesized to transduce agonist binding into channel
gating. Thus, the mechanism of inhibition of AMPARs
for these compounds is likely to be disruption of this
transduction process.
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Derived from Adjacent Subunits
Based on the finding that GYKI/CP sensitivity depends
on both S1-M1 and S2-M4 linkers, a question remains
whether their antagonistic action proceeds via an intra-
or intersubunit binding mode. To distinguish between
the two possibilities, we tested coexpression of CP-
sensitive and CP-insensitive subunits carrying addi-
tional mutations that allowed preferential activation of
only one subunit type in the heteromeric assembled re-
ceptors. Our experimental approach was based on the
assumption that agonist binding to each subunit in
a given receptor additively contributes to channel gat-
ing in a subunit-independent manner. Evidence for this
assumption comes from single-channel analysis on
recombinant and native channels (Rosenmund et al.,
1998; Smith and Howe, 2000) demonstrating that AM-
PARs open into three graded and defined conductance
states—small, medium, and large (w6, 12, and 18 pS for
GluR2)—corresponding to two, three, and four agonist-
bound subunits per receptor (binding to only one sub-
unit is apparently undetectable or ineffective). Accord-
ing to this assumption, in heteromeric receptors
containing both antagonist-sensitive and -insensitive
subunits, currents mediated by agonist binding to the
antagonist-sensitive subunits should be fully inhibited.
On the other hand, currents mediated by agonist bind-
ing to the antagonist-insensitive subunits should not
be inhibited if the antagonist exclusively binds within
the neighboring subunits. However, if the antagonist
binds between S1-M1 and S2-M4 linkers of neighboring
subunits, an intermediate inhibition value would be ex-
pected in both experimental paradigms (as observed
for subunits mutated in only one of these linkers; Figure
4B). Because CP is more potent than GYKI, the follow-
ing experiments were done with subunits engineered
to have or lack sensitivity to CP.
For the first scenario, we used the CP-insensitive mu-
tant of GluR3, R3(D543-E548, V818I), in which we addi-
tionally mutated the conserved arginine in the binding
pocket (R509) to alanine, therefore impairing glutamate
binding [marked as R3Q(CP
2/Glu2); Figure 5A]. For the
CP-sensitive subunit, we used the edited form of
GluR2 containing an arginine (R) at the Q/R-edited site
in M2 (Seeburg, 1996) [marked as R2R(CP
+/Glu+); Figure
5A]. Based on previous studies, the R form generates
low-conducting receptors (Hume et al., 1991; Mansour
et al., 2001; Swanson et al., 1997) that are largely
retained in the endoplasmic reticulum (Greger et al.,
2002); however, when assembled with unedited sub-
units containing glutamine at this position (Q form),
the channels are targeted to the membrane and are
highly conducting. As expected, no currents could be
recorded from either one of these subunits when ex-
pressed alone, while protein expression was signifi-
cantly high (Figure 5A). In contrast, when they were
coexpressed at a 1:1 ratio, we obtained large glutamate-
evoked currents, and these were partially inhibited by
CP (57% 6 9%; n = 7). At these conditions, glutamate-
evoked currents are mediated only by the heteromeric
channels in which the R2R(CP
+/Glu+) subunits contrib-
ute the active glutamate-binding sites. Therefore, the
observation that the activation of these channels by
glutamate binding only to the CP-sensitive subunitswas not fully inhibited by CP suggests that CP most
probably binds between neighboring subunits. As a
control, we used the R509A mutation in the GluR3 wild-
type background, thus having an operational CP bind-
ing site, but not for glutamate [marked as R3Q(CP
+/
Glu2]; Figure 5A), and when this subunit was expressed
with R2R(CP
+/Glu+) the resulting glutamate-evoked
currents where fully inhibited by CP (97% 6 2%, n = 7;
Figure 5A).
Figure 5. Coexpression of CP-Sensitive and CP-Insensitive Sub-
units Suggests an Intersubunit Binding Mode
(A) Expressions (alone and at 1:1 ratio) of R3(D543-E548, R509A),
the CP-insensitive GluR3 subunit lacking a functional glutamate
binding site marked as R3Q(CP
2/Glu2), and edited GluR2, the
CP-sensitive GluR2 R-form subunit marked as R2R(CP
+/Glu+).
(B) Expressions (alone and at 1:1 ratio) of R1(D533N, I806V), the
CP-insensitive GluR1 subunit marked as R1Q(CP
2/AMPA+), and un-
edited Q-form R2(L650T), the CP-sensitive GluR2 subunit lacking
functional AMPA binding-site marked as R2Q(CP
+/AMPA2). All sub-
units are included in addition to the L-to-Y nondesensitizing muta-
tion. Bars represent current amplitudes (6SD) mediated by the re-
spective agonist (glutamate, 1 mM; AMPA, 0.1 mM) in the absence
or presence of CP (30 mM) as indicated (n = 7–10 oocytes each).
Western blot analysis of subunit protein expression is shown on
the bottom. Experiments were repeated twice with similar results.
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insensitive mutant of GluR1, R1(D533N, I806V) [marked
as R1Q(CP
2/AMPA+); Figure 5B], with the unedited Q
form of GluR2 having the mutation L650T, which impairs
binding of the agonist AMPA but not of glutamate (Arm-
strong et al., 2003) but otherwise carries an intact bind-
ing site for CP [marked as R2Q(CP
+/AMPA2); Figure 5B].
As expected, when expressed alone, R1Q(CP
2/AMPA+)
exhibited similar current amplitudes when activated by
glutamate or AMPA, and these currents were hardly af-
fected by CP (5% 6 2% and 7% 6 3%, respectively;
n = 10). Conversely, glutamate but not AMPA activated
the R2Q(CP
+/AMPA2) receptors, and this activation
was fully inhibited by CP (98%6 1%; n = 10). When these
subunits were coexpressed at a 1:1 ratio, we observed
large glutamate-evoked currents and intermediate
AMPA-evoked currents, and both were inhibited by CP
(36% 6 8% and 70% 6 6, respectively; n = 10). Under
these conditions, glutamate-evoked currents must be
mediated by all resulting receptor combinations, while
AMPA-evoked currents must be exclusively mediated
by receptors containing the CP-insensitive R1Q(CP
2/
AMPA+) subunits, thereby exhibiting the intermediate
amplitude of AMPA/glutamate-evoked currents (38% 6
3%) as compared to the homomeric expressions of
R1Q(CP
2/AMPA+) (97% 6 3%) and R2Q(CP
+/AMPA2)
(0.6% 6 0.5%), respectively. According to the working
hypothesis of subunit-independent gating, if binding of
CP is exclusively within the subunit monomer, AMPA-
evoked currents should not be inhibited by the antago-
nist, while glutamate-evoked currents should be par-
tially prevented. The fact that AMPA-evoked currents
were significantly inhibited by CP thus supports the
intersubunit-binding model.
Discussion
In the present study, we have mapped the binding site
for two noncompetitive antagonists, GYKI and CP, on
the AMPAR. Although these molecules are representa-
tives of two structurally distinct classes of compounds,
radioligand-binding studies indicated that the binding
site for these two drugs essentially overlaps (Menniti
et al., 2000). Both GYKI and CP are highly selective for
inhibition of AMPAR as compared to the closely related
KAR, as shown previously (Lazzaro et al., 2002; Pater-
nain et al., 1995) and as demonstrated here (Figure 1).
Using a domain-swapping strategy between the AM-
PAR GluR3 and the KAR GluR6 (Figure 3) followed by
site-directed mutagenesis (Tables S1 and S2), we dem-
onstrate that the residues critical for conferring GYKI/
CP sensitivity are located in small regions of the AMPAR
that unambiguously lie close to the putative junction at
the plasma membrane of the linkers S1 and S2 with
the transmembrane-spanning regions of M1 and M4, re-
spectively. At the amino-acid level, the residues critical
for GYKI and CP binding are distinct but in close prox-
imity to one another (Figure 4), consisting of the overlap-
ping binding sites on one hand and the distinct struc-
tures of GYKI and CP on the other. Substitutions in
S1-M1 were more effective on CP, while those in S2-
M4 affected GYKI binding to a greater extent. Signifi-
cantly, however, substitutions on both the S1-M1 and
S2-M4 linkers were required to fully convert the sensitiv-ity between GluR3 and GluR6 and vice versa (Figure 4).
Thus, it appears that the GYKI/CP binding site spans
these two linker regions.
The question remained as to whether the GYKI/CP
binding site spanned S1-M1 and S2-M4 within a single
subunit or across adjacent subunits. To investigate
these two possibilities, we performed coexpression and
activity studies in oocytes with AMPAR subunits in which
either the agonist binding or CP binding was abolished
by appropriate point mutations. This approach assumed
that each subunit gates independently (Rosenmund
et al., 1998; Smith and Howe, 2000). We observed under
several conditions that the degree of inhibition of chan-
nel activity by CP could only be accounted for by an inter-
action of the molecule with linkers derived from adjacent
subunits (Figure 5). Thus, the GYKI/CP binding site re-
sides in the multimeric complex of the fully assembled
AMPAR.
Manipulations that reduce AMPAR desensitization
(i.e., increase open state) significantly decreased the
potency of GYKI and CP for inhibition of AMPAR activity
(Figure1). These manipulations included both pharma-
cological (addition of CTZ; Patneau et al., 1993) and
structural (L-to-Y mutation; Stern-Bach et al., 1998), in
both cases resulting in block of receptor desensitiza-
tion. Radioligand-binding studies in rat-brain mem-
branes revealed that the binding affinity of CP is signif-
icantly reduced (>10-fold) by the presence of agonist
(AMPA or glutamate) plus CTZ, i.e., conditions that en-
rich for the presence of receptors in the open, nonde-
sensitized state (Figure 2). In addition, electrophysiolog-
ical measurements in wild-type AMPARs (i.e., with
intact desensitization) revealed that the dissociation
constant of GYKI from the open state is 2-fold larger
than that from the closed state (Figure 2). These data in-
dicate that GYKI and CP bind better to a closed state of
the AMPAR channel. The apparent loss of this binding
site in the open, nondesensitized receptors is parsimo-
niously accounted for by a conformational change in the
S1-M1 and S2-M4 linkers that distort the binding site
such that GYKI and CP affinities are reduced. In addi-
tion, the tight correlation between GYKI/CP binding
and agonist efficacy to open the channel (Figure 2) fur-
ther provides a strong link between gating state and re-
arrangements at the linker interface.
The effects of gating on GYKI/CP binding to S1-M1
and S2-M4 linkers thus suggest movement of these link-
ers during channel gating. We propose that this move-
ment is part of the mechanism transducing agonist
binding into channel opening, and restriction of this
movement underlies the molecular mechanism of inhibi-
tion by these compounds (see Figure 6 for illustrative
model). The effects of gating on GYKI/CP binding may
be due to separation of the linkers one from another
and/or conformational changes within the linkers. Mod-
els of AMPAR gating suggest that agonist binding leads
to outward lateral rotation of the individual subunits in
the dimeric assembly (Figure 6, arrow 1; Sun et al.,
2002). Such a rotation is thus likely to increase the dis-
tance between S1-M1 and S2-M4 linkers from adjacent
subunits, making binding of GYKI/CP to two binding
sites on adjacent subunits less likely. Conformational
changes within the linker domains are supported by
the observation that reduction of binding to one of the
Neuron
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binding (Table S3). Thus, a model providing the simplest
explanation for the present findings with GYKI and CP
is that these compounds, by binding to the S1-M1 and
S2-M4 linker regions, stabilize a configuration of these
linkers such that agonist binding fails to induce a suffi-
cient conformational change to pull open the channel
(Figure 6).
Overall, our findings confirm previous models but re-
veal new aspects of AMPAR physiology. Studies on the
Figure 6. Schematic Model for GYKI/CP Inhibition of AMPAR
Shown are two subunits (A and B) forming one out of the two
dimers assembling an active channel (the NTD is omitted). Four
equilibrium states of AMPAR receptor/channel modes are drawn:
C, agonist-unbound/closed-resting; CGlu, agonist-bound/closed-
resting; OGlu, agonist-bound/open-conducting; DGlu, agonist-bound/
closed-desensitized. Agonist (black circles) docking in D1 induces
rotation of D2 (arrow 1), closing the binding cleft. The movement is
greater for full agonists such as glutamate and AMPA, intermediate
for partial agonist like kainate, and almost none for competitive an-
tagonists like CNQX. This movement is assumed to produce chan-
nel opening (arrow 2). In the next step (arrow 3), breakdown of the
D1 interface promotes closing of the channel, entering into the de-
sensitized state. This step is inhibited by CTZ (white circle) binding
in the D1 dimer interface and by the L-to-Y mutation. Based on
present results, we suggest that the dimer interface extends to
the linker regions. GYKI/CP (black rod) bind to the linkers origi-
nated from adjacent subunits. GYKI/CP binding affinity is high for
agonist-unbound (C) or desensitized (DGlu) states but low to acti-
vated channels (OGlu). GYKI/CP binding to the S1-M1 and S2-M4
linker regions stabilize a configuration of these linkers such that ag-
onist binding fails to induce a sufficient conformational change to
pull open the channel. Thus, the interplay between rearrangements
at the D1 dimer interface and those at the linker regions explains
the allosteric interaction observed between CTZ and GYKI/CP.Lurcher mutation (Klein and Howe, 2004; Kohda et al.,
2000) and utilizing cysteine-substituted mutagenesis
(Sobolevsky et al., 2003, 2004; Yelshansky et al., 2004)
have established that the S2-M3 linker plays an impor-
tant role in transduction of agonist binding to channel
gating in the AMPAR. Residues significant for GYKI/
CP action on this segment could not be revealed by
the chimeric screening approach because segment
S2-M3 is identical in GluR3 and GluR6 subunits. Yet,
in addition to S2-M3, our results with GYKI and CP dis-
close a crucial role of the other two linkers in gating. Of
special significance is the involvement of S2-M4, which
has been systematically omitted from models of chan-
nel gating (Wollmuth and Sobolevsky, 2004), mostly
due to lack of homology of M4 to the potassium channel
(Wo and Oswald, 1995) and its absence in GluR0, a pro-
karyotic glutamate-gated channel (Chen et al., 1999).
Therefore, a plausible interpretation of our data is that
all three linker regions are involved in mediating the
transduction of agonist binding to channel gating of
the AMPAR. Yet, it is possible that the state depen-
dence may arise solely from the movement of M3 and
that GYKI/CP binding to S1-M1 and S2-M4 allosterically
interferes with this movement. However, previous stud-
ies on NMDAR have implicated the S1-M1 linker in de-
sensitization (Krupp et al., 1998; Villarroel et al., 1998),
and cysteine-substituted mutagenesis showed a state-
dependent accessibility of residues in S1-M1 and S2-
M4 linkers to cysteine-modifying reagents (Sobolevsky
et al., 2002), further supporting their direct involvement
in channel gating.
A notable observation from the site-directed muta-
genesis was the ability to confer to GluR6 complete sen-
sitivity to either GYKI or CP through single-amino-acid
substitutions on the S1-M1 and on S2-M4 segments
(Figure 4). The homology of the S1-M1 and S2-M4 link-
ers between GluR3 and GluR6 is quite low. However, the
fact that complete sensitivity to GYKI/CP can be con-
ferred through these amino-acid substitutions suggests
a high degree of topological homology. Furthermore,
since the GYKI/CP binding site occurs between adja-
cent subunits, the topological homology in this region
is conserved across that multimeric receptor complex.
This finding adds support to the prevailing hypothesis
that there is a high degree of conservation in the gating
mechanism across the different subtypes of glutamate
receptors (Erreger et al., 2004).
In summary, our results define sites of interaction of
two noncompetitive antagonists, GYKI and CP, with the
AMPAR, providing a conceptual mechanism for non-
competitive antagonism of receptor activity. It comes
from the fact that domain movements leading to channel
opening are likely restricted upon antagonist binding. In-
deed, AMPA receptors N-terminal seem to undergo
a substantial movement upon agonist binding, leading
to pulling apart the linker segments forming the gating
pathway. Interestingly, the GluR6 residue G821 in S2-
M4, found to play a significant role in conferring sensitiv-
ity to GYKI when mutated to the corresponding alanine
of GluR3 (Table S2), enables enhancement of GluR6 cur-
rents by local anesthetics such as halothane (Minami
et al., 1998). This raises the intriguing possibility that
compounds that affect conformational changes in
the linkers could modulate up or down the coupling
Mechanism of AMPA Receptor Allosteric Inhibition
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mains, thus acting as positive or negative allosteric
modulators. Once atomic structural resolution is avail-
able for this region, the identification and definition of
these sites would allow rational drug design of mole-
cules limiting or enhancing AMPAR or KAR activity in
an agonist-independent manner. Such compounds may
provide the much-needed pharmacological probes to
explore new therapeutic uses of glutamate-receptor-
subtype-selective antagonists.
Experimental Procedures
Molecular Biology and In Vitro cRNA Transcription
All AMPAR constructs used in this study contained the flip isoform.
The majority of the chimeras presented in Figure 3 have been
described previously (Ayalon and Stern-Bach, 2001; Stern-Bach
et al., 1994, 1998). The other chimeras were constructed by a similar
approach. Point mutations were constructed by the QuikChange
method (Stratagene, La Jolla, CA). The templates GluR3(Q, flip)
GluR1(Q, flip), and GluR6(VCQ) were originally obtained from S.F.
Heinemann (Salk Institute, La Jolla, CA). Mutants were first inserted
into the pGEMHE vector (a gift from E. Liman, University of Southern
California, Los Angeles, CA) for expression in oocytes and subse-
quently moved to pCDNA3 (Invitrogen, San Diego, CA) for expres-
sion in HEK293 cells. The regions amplified by PCR were verified
by double-strand DNA sequencing. In all cases, numbering of amino
acids starts from the first methionine of the ORF. GluR2(L650T)
(L493Y/ Q-form/ flip) in pGEMHE was obtained from E. Gouaux (Co-
lumbia University, New York, NY). For expression in oocytes, plas-
mids were linearized with NheI, and capped cRNA was transcribed
in vitro using T7 RNA polymerase (mMessage mMachine; Ambion,
Austin, TX). The quality of transcripts was assessed by agarose
gel electrophoresis and ethidium bromide staining and quantified
by analytical UV spectroscopy (ND-1000; NanoDrop Technologies,
Inc. Rockland, DE).
Heterologous Expression and Electrophysiological Recordings
Stage V-VI Xenopus laevis oocytes were prepared as described pre-
viously (Stern-Bach et al., 1994). Oocytes were injected up to 24 hr
after preparation with 5–10 ng of cRNA in 50 nl/oocyte and were as-
sayed 1–3 days later. Two-electrode voltage-clamp recordings were
carried out at room temperature using GeneClamp500 connected to
DIGIDATA1200 and pCLAMP8 (Axon Instruments, Foster City, CA).
Pulled-glass capillaries (Sutter Instruments, Novato, CA) were filled
with 3 M KCl and had a resistance of 0.5–1 MU. Oocytes were contin-
uously perfused with recording solution containing 10 mM HEPES
(pH 7.4), 90 mM NaCl, 1 mM KCl, and 1.8 mM MgCl2 or CaCl2. Where
indicated, to avoid interference from receptor desensitization, oo-
cytes were treated with cyclothiazide (0.1 mM, mixed in the agonist
solution; RBI, Natick, MA) or with concanavaline A (ConA; 1 mg/ml,
5–10 min before recording; Sigma, St. Louis, MO) to block AMPAR
or KAR desensitization, respectively. Currents were usually re-
corded at 270 mV, unless otherwise stated. Glutamate and kainate
were obtained from Sigma (St. Louis, MO), AMPA and CNQX were
obtained from Tocris (Bristol, UK), GYKI-53655 (LY300168) was
a gift from Eli Lilly and Company (Lilly Corporate Center, Indianapo-
lis, IL), and CP-465,022 was synthesized in-house (Pfizer, Groton,
CT). Dose-inhibition curves were usually constructed by applying
one to three concentrations per oocyte of antagonist mixed in ago-
nist solution, and currents (I) were normalized to the steady-state
current obtained with agonist alone (I0). Data were analyzed using
ORIGIN 6.0 software (OriginLab, Northampton, MA). Receptor ex-
pression and electrophysiological measurements in HEK293 cells
were done as previously described (Lazzaro et al., 2002). Currents
were measured under the whole-cell configuration of the patch-
clamp technique, and solutions were applied with a fast-perfusion
system as previously (e.g., Paternain et al., 2003). While the IC50s
for GYKI inhibition of AMPARs were similar in oocytes and HEK293
cells, these values differed for CP by w5-fold in oocytes and HEK
cells. Values in HEK293 cells were similar to those observed for CP
inhibition of native AMPA receptors (Lazzaro et al., 2002).Rat Forebrain Membrane Preparation and [3H]CP-526,427
Binding
Membrane preparation and binding assays were done as previously
described (Menniti et al., 2000). Forebrains of adult male Sprague-
Dawley or SABRA rats were homogenized in 0.32 M sucrose at 4ºC.
The crude nuclear pellet was removed by centrifugation at 10003 g
for 10 min, and the supernatant was centrifuged at 17,000 3 g for
25 min. The resulting pellet was resuspended in 5 mM Tris acetate
(pH 7.4) at 4ºC for 10 min to lyse cellular particles and was again
centrifuged at 17,000 3 g. The resulting pellet was washed twice
in Tris acetate, resuspended at 10 mg of protein/ml and stored at
270ºC until use. Immediately before binding assays, membranes
were thawed, homogenized, and diluted to 0.5 mg of protein/ml
with 50 mM Tris-HCl (pH 7.4). For competition assays, the various
compounds were added to the membranes and incubated for 10
min at 30ºC in a shaking water bath prior to the addition of 3 nM
[3H]CP-526,427 (specific activity, 24.36 Ci/mmol). After incubation
for an additional 20 min, samples were filtered onto Whatman
GFB glass-fiber filters, washed twice with ice-cold Tris-HCl buffer,
and the radioactivity trapped on the filter was quantified by liquid
scintillation counting. Nonspecific binding was determined in paral-
lel incubations containing 50 mM unlabeled CP-465,022. Specific
binding was defined as total binding minus nonspecific binding.
Scatchard analyses were performed similarly by incubating differ-
ent concentrations of [3H]CP-526,427 with membranes. Binding as-
says performed on intact oocytes or on membranes prepared from
either oocytes or HEK293 cells (Stern-Bach et al., 1994) expressing
various combination of AMPAR subunits resulted in onlyw5% spe-
cific binding using radioligand concentrations of 3–100 nM; thus
preventing reliable measurements on recombinant subunits. This
high background most probably resulted from combination of the
high lipophilicity of CP (w50% background on rat-brain mem-
branes; Menniti et al., 2000) and relative low receptor expression
as compared to the native material.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/48/2/279/DC1/.
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